Your point about the control arm is the one that keeps nagging at me. In a 122-person unblinded trial, observation with hydroxyurea as the comparator means the survival gap — 14.7 to 24 months — is doing a lot of work against a control that isn't really a treatment arm in the modern maintenance sense. Add the moving pieces you flag — the planned 140 shrinking to 122, a single overall-survival analysis at 80 deaths, and follow-up quietly stretched from 52 weeks to five years on the registry — and the headline number starts to look less like a result and more like a hypothesis waiting for a properly powered, placebo-controlled test. I hope it replicates; AML maintenance is exactly where an off-the-shelf peptide vaccine would be transformative if real. But the Washington Post treatment of a small open-label study as near-breakthrough is precisely the pattern that burns patients and clinicians alike when the confirmatory trial lands differently.
In most “scientific” studies these days you can go ahead and make up the story you want and then go find the data you need to support it. Especially if it means selling something.
"Optimism is great, critical appraisal is even better."
you just gotta believe in something Vinay; strong personal conviction; intense belief; that's the way to go ....... even make it up as you go along; our brave new world .......
Small numbers, I get that...is the control not SoC? An old tech and not being blinded does not mean anything bad necessarily..can you expound on your skepticism more specifically? Thanks
Question: "Why is this small randomized study making the mainstream news?"
Answer: Because they buy ads.
Asked and answered. NEXT!!!
Your point about the control arm is the one that keeps nagging at me. In a 122-person unblinded trial, observation with hydroxyurea as the comparator means the survival gap — 14.7 to 24 months — is doing a lot of work against a control that isn't really a treatment arm in the modern maintenance sense. Add the moving pieces you flag — the planned 140 shrinking to 122, a single overall-survival analysis at 80 deaths, and follow-up quietly stretched from 52 weeks to five years on the registry — and the headline number starts to look less like a result and more like a hypothesis waiting for a properly powered, placebo-controlled test. I hope it replicates; AML maintenance is exactly where an off-the-shelf peptide vaccine would be transformative if real. But the Washington Post treatment of a small open-label study as near-breakthrough is precisely the pattern that burns patients and clinicians alike when the confirmatory trial lands differently.
Anymore need to be said....
"Any intelligent and honest oncologist or drug developer..."
In most “scientific” studies these days you can go ahead and make up the story you want and then go find the data you need to support it. Especially if it means selling something.
I'm more likely to believe it when they offer it free to AML patients.
"Optimism is great, critical appraisal is even better."
you just gotta believe in something Vinay; strong personal conviction; intense belief; that's the way to go ....... even make it up as you go along; our brave new world .......
Small numbers, I get that...is the control not SoC? An old tech and not being blinded does not mean anything bad necessarily..can you expound on your skepticism more specifically? Thanks